Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.7252W HIGH $4.90
Volume
331.00
Value Traded
21.79 K
Short % Float
0.22%
-3.37%Week
-5.63%1 Month
+11.36%3 Month
+15.52%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
32.41 M
EPS (TTM)
-0.31
P/E Ratio
-
Ent. Value
37.53 M
Total Shares
8.07 M
Float Shares
4.20 M
Insiders
47.86%
Institutions
13.72%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CCEL Catalyst Timeline
Dated clinical, regulatory and corporate events for Cryo-Cell International Inc.
Past FDA Catalysts and PDUFA Decisions
How CCEL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D30 / 100
Pipeline Score
$3M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 69%
Micro Cap(rank 454 of 658)
Percentile Rank
Cryo-Cell International Inc. faces pipeline headwinds (30/100), with $50M risk-adjusted pipeline value, led by Cord Tissue Mesenchymal Stromal Cells in Autism (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cord Tissue Mesenchymal Stromal Cells Monoclonal antibodyCompletedNCT04089579 | Autism | Phase 2 | COMPLETED | 137 | Feb 1, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every CCEL program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| TAYMANS JILL MOfficer (VP Finance, CFO) | Option | -7,500 52,896 held | $3.10 | 05/28/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CCEL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CCEL for Q2 2026. | ||||
CCEL Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CCEL ranks across every disease it competes in
Competitive Position is a premium feature
See how CCEL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCCEL News
-CCEL
Jul 15, 2026Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2026 Financial Results
Cryo-Cell International, Inc. reported its fiscal second quarter 2026 financial results, showing a slight revenue decrease to $7.8 million. However, net income improved to $555,000, reflecting a positive trend in profitability. The company continues to expand its services, including partnerships and new offerings, despite facing challenges in revenue generation.
Read more →-CCEL
May 8, 2026Irene Smith 813-749-2102 Ismith@cryo-cell.com CRYO-CELL RECEIVES ACCEPTANCE OF COMPLIANCE PLAN FROM NYSE AMERICAN OLDSMAR, FL. –
Cryo-Cell International, Inc. has received approval from NYSE American for its compliance plan to address listing standards. The company was previously notified of a stockholders' deficit and net losses over recent years. With an extended compliance period until September 2027, Cryo-Cell's stock will continue to trade on the NYSE American, pending adherence to the plan. However, there are risks of delisting if compliance isn't achieved by the deadline.
Read more →-CCEL
Apr 28, 2026Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks
Cryo-Cell International has successfully renewed its FACT accreditation for cord blood banking, extending its recognition until April 2029. This accreditation confirms compliance with the highest international standards in cellular therapy, reinforcing the company's commitment to quality and safety. As the first private cord blood bank to receive this accreditation, Cryo-Cell continues to set benchmarks in the industry.
Read more →-CCEL
Apr 14, 2026Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results
Cryo-Cell International, Inc. reported its fiscal first quarter 2026 financial results, revealing a revenue decline to $7.68 million from $7.97 million in the prior year. The net income also fell sharply to approximately $47,000 compared to $283,000 in the same quarter of 2025. The company continues to operate as a leading private cord blood bank, storing over 250,000 specimens.
Read more →-CCEL
Mar 12, 2026Irene Smith 813-749-2102 Ismith@cryo-cell.com CRYO-CELL RECEIVES NYSE AMERICAN CONTINUED LISTING NOTICE OLDSMAR, FL. –
Cryo-Cell International, Inc. has received a continued listing notice from NYSE American due to non-compliance with certain listing standards. The notice cites a stockholders' deficit and net losses in two of the past three fiscal years. Despite this, the company's stock will continue to trade while it formulates a compliance plan. If accepted, the company would have up to 18 months to regain compliance, although uncertainties remain about their ability to do so.
Read more →-CCEL
Feb 27, 2026Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025
Cryo-Cell International, Inc. reported its financial results for the fiscal year ending November 30, 2025, showing a slight decrease in revenue to $31.6 million and a net loss of $2.4 million. The company faced challenges, including an impairment charge of $4.4 million related to inventory. Despite these setbacks, Cryo-Cell maintains a significant presence in the cord blood banking industry.
Read more →-CCEL
Oct 15, 2025Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2025 Financial Results
Cryo-Cell International, Inc. reported its fiscal third quarter 2025 results, showing a revenue decrease to $7.83 million and a net income drop to $749,000. The company, a pioneer in private cord blood banking, continues to operate under stringent quality standards and has partnerships for public banking. However, it faces risks related to future performance and market competition.
Read more →-CCEL
Aug 14, 2025▼ -9.7%on this news
Cryo-Cell International, Inc. Provides Dividend Update
Cryo-Cell International, Inc. has announced that it will not issue a quarterly cash dividend for the third quarter of fiscal 2025 due to lower-than-expected profitability. The company indicated that future decisions regarding dividends will be influenced by financial performance and strategic priorities. This announcement raises concerns about the company's financial health and future dividend prospects.
Read more →-CCEL
Jul 15, 2025Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results
Cryo-Cell International, Inc. reported its fiscal second quarter 2025 financial results, showing a slight revenue decline to $7.9 million and a net income decrease to $356,000. Despite these challenges, the company maintains its status as a leader in private cord blood banking, serving over 500,000 families globally. The company continues to expand its services and partnerships in cellular therapies.
Read more →-CCEL
May 8, 2025Irene Smith 813-749-2102 Ismith@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL ANNOUNCES CASH DIVIDEND OLDSMAR, FL –
Cryo-Cell International, Inc. has announced a quarterly cash dividend of $0.15 per share, which is a reduction from previous payouts, due to the current economic environment. The dividend will be paid on May 30, 2025, to shareholders recorded by May 21, 2025. The company emphasizes the ongoing evaluation of its dividend policy, indicating it may change in the future. Cryo-Cell remains a pioneer in cord blood banking, complying with industry regulations and striving for quality in its services.
Read more →-CCEL
Oct 30, 2024▲ +25.6%on this news
Irene Smith 813-749-2102 Ismith@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL declares INITIATION OF regular quaRterly CASH DIVIDEND OLDSMAR, FL –
Cryo-Cell International, Inc. announced the initiation of a regular quarterly cash dividend at an initial rate of $0.25 per share for shareholders of record as of November 15, 2024. The payment is expected to occur on November 29, 2024. This decision aims to enhance shareholder value while the Board evaluates the dividend policy based on the company's performance and capital needs. Cryo-Cell, the world's first private cord blood bank, has garnered trust from over 500,000 parents across 87 countries.
Read more →-CCEL
Oct 15, 2024Irene Smith 813-749-2102 Ismith@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD Quarter 2024 FINANCIAL RESULTS OLDSMAR, FL –
Cryo-Cell International, Inc. (CCEL) announced its fiscal third quarter results for 2024, showing a revenue increase to $8.07 million from the previous year's $7.87 million. The company's net income also rose to $1.05 million, up from $681,000 in the same quarter last year. Additionally, Cryo-Cell detailed its ongoing exploration of strategic alternatives and the delay of its Celle Corp. spinoff due to pending arbitration with Duke University. The possibility of introducing quarterly dividends for shareholders was also highlighted in the announcement.
Read more →-CCEL
Mar 25, 2024▲ +7.6%on this news· ran to +25% by day 1
Irene Smith 813-749-2102 Ismith@cryo-cell.com CRYO-CELL ANNOUNCES PLANS TO EXPLORE STRATEGIC ALTERNATIVES AND SPIN-OFF CELLE CORP. TO MAXIMIZE SHAREHOLDER VALUE OLDSMAR, FL. –
Cryo-Cell International, Inc. announced plans to explore strategic alternatives and is set to spin off its new subsidiary, Celle Corp., to its shareholders. This decision is aimed at maximizing shareholder value through potential equity or debt financings and possible company mergers. The spin-off is anticipated to occur in Cryo-Cell's 2nd or 3rd fiscal quarters and will involve transferring certain assets and liabilities to Celle Corp. Shareholders may receive the spin-off in the form of a stock dividend. Further details will be disclosed in future SEC filings.
Read more →-CCEL
Mar 16, 2022Irene Smith 813-749-2102 Ismith@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL ANNOUNCES EXTRAVAULT BIOREPOSITORY SERVICE OLDSMAR, FL –
For Immediate Release Contact: Ismith@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL ANNOUNCES EXTRAVAULT BIOREPOSITORY SERVICE OLDSMAR, FL March 16, 2022 Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the Company ), the world's first private cord blo
Read more →-CCEL
Feb 22, 2022▲ +7%on this news
Irene Smith 813-749-2102 Ismith@cryo-cell.com CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2021 OLDSMAR, FL. –
For Immediate Release Contact: Irene Smith Ismith@cryo-cell.com CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2021 OLDSMAR, FL. February 22, 2022 Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the Company ), the world's first pri
Read more →-CCEL
Oct 15, 2021Irene Smith 813-749-2102 Ismith@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD Quarter 2021
For Immediate Release Contact: Irene Smith 813-749-2102 Ismith@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD Quarter 2021 FINANCIAL RESULTS OLDSMAR, FL - October 15, 2021 - Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the "Co
Read more →-CCEL
Sep 20, 2021▼ -5.4%on this news
Cryo-Cell International Announces Changes To Its Board of Directors Miami, Fl
Cryo-Cell International Announces Changes To Its Board of Directors Miami, Fl, September 20, 2021 (GLOBENEWSWIRE) -- Cryo-Cell International, Inc. (Nasdaq:CCEL), the leader in cord blood and cord tissue cryopreservation services, announces the appointment of Mr. Mark Portnoy and
Read more →-CCEL
Jul 15, 2021Diane Glanz, Rph, PharmD Investor Relations Consultant 813-749-2195 DGlanz@Cryo-Cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND Quarter 2021
For Immediate ReleaseContact: Diane Glanz, Rph, PharmD Investor Relations Consultant DGlanz@Cryo-Cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND Quarter 2021 FINANCIAL RESULTS OLDSMAR, FL - July 15, 2021 - Cryo-Cell International, Inc. (OTC:QB Markets Grou
Read more →-CCEL
Apr 14, 2021David Portnoy Chairman and Co- Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIrst Quarter 202
For Immediate ReleaseContact: Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. dportnoy@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIrst Quarter 2021 FINANCIAL RESULTS OLDSMAR, FL - April 14, 2021 - Cryo-Cell International, Inc. (OT
Read more →-CCEL
Feb 24, 2021David Portnoy Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2020 OLDSMAR, FL.
For Immediate ReleaseContact: Cryo-Cell International, Inc. dportnoy@cryo-cell.com CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2020 OLDSMAR, FL. - February 24, 2021 - Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the "Company"),
Read more →About Cryo-Cell International Inc.
Headquarters700 BROOKER CREEK BLVD, OLDSMAR, FL, 34677
BIOPHARMAWATCH ELITE PLUS
Trade the next CCEL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime